Department of Laboratory Animal Science, Kunming Medical University, Kunming, China.
Basic Medical College, Kunming Medical University, Kunming, China.
Pharm Biol. 2021 Dec;59(1):311-320. doi: 10.1080/13880209.2021.1900879.
Current medicine for Alzheimer's disease (AD) cannot effectively reverse or block nerve injury. Traditional Chinese Medicine practice and research imply (Fuzi) may meet this goal.
Analysing the anti-AD effect of Fuzi and its potential molecular mechanism.
AD model cells were treated with Fuzi in 0-300 mg/mL for 24 h in 37 °C. The cell viability (CV) and length of cell projections (LCP) for each group were observed, analysed, and standardised using control as a baseline (CV and LCP). The Fuzi and AD relevant genes were identified basing on databases, and the molecular mechanism of Fuzi anti-AD was predicted by network analysis.
Experiment results showed that Fuzi in 0.4 mg/mL boosted LCP (LCP = 1.2533, ≤ 0.05), and in 1.6-100 mg/mL increased CV (CV from 1.1673 to 1.3321, ≤ 0.05). Bioinformatics analysis found 17 Fuzi target genes (relevant scores ≥ 20), showing strong AD relevant signals (RMS_ ≤ 0.05, related scores ≥ 5), enriched in the pathways regulating axon growth, synaptic plasticity, cell survival, proliferation, apoptosis, and death ( ≤ 0.05). Especially, and interacted with protein and located in the key point of the "Alzheimer's disease" pathway.
These results suggest that Fuzi may have therapeutic and prevention potential in AD, and and may be the core of the pathways of the Fuzi anti-AD process. Fuzi should be studied more extensively, especially for the prevention of AD.
目前治疗阿尔茨海默病(AD)的药物无法有效逆转或阻止神经损伤。中医实践和研究表明,(附子)可能达到这一目标。
分析附子的抗 AD 作用及其潜在的分子机制。
在 37°C 下,将 AD 模型细胞用附子处理 0-300mg/ml,24h。观察、分析并以对照组为基准(CV 和 LCP)对各组细胞活力(CV)和细胞突起长度(LCP)进行标准化。根据数据库确定附子和 AD 相关基因,并通过网络分析预测附子抗 AD 的分子机制。
实验结果表明,附子在 0.4mg/ml 时可增加 LCP(LCP=1.2533,≤0.05),在 1.6-100mg/ml 时可增加 CV(CV 从 1.1673 增加到 1.3321,≤0.05)。生物信息学分析发现 17 个附子靶基因(相关评分≥20),显示出强烈的 AD 相关信号(RMS_≤0.05,相关评分≥5),富集在调节轴突生长、突触可塑性、细胞存活、增殖、凋亡和死亡的途径中(≤0.05)。特别是,和与蛋白相互作用,位于“阿尔茨海默病”途径的关键点。
这些结果表明,附子可能具有治疗和预防 AD 的潜力,和可能是附子抗 AD 过程中途径的核心。应该更广泛地研究附子,特别是预防 AD。